Gossamer Bio

Biotech Regulation And Cash Burn Will Constrain Future Prospects

AnalystLowTarget

Not Invested

Community Contributor

Published

12 Aug 25

AnalystLowTarget's Fair Value

US$1.25

105.6% overvalued

04 Sep

US$2.57

144.8%

-8.9%

144.8%

-8.9%

You can edit this narrative until Aug 12 10:36 PM. Then, changes will post as Updates.

Author's Valuation

US$1.25105.6% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$1.25

105.6% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

52.58%

Biotech revenue growth rate

8.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.35%

Calculation

US$11.01m

Earnings '28

32.01x

PE Ratio '28

US$352.47m

Market Cap '28

US$352.47m

Market Cap '28

229.73m

No. shares '28

US$1.53

Share Price '28

US$1.53 Share Price '28

Discounted to 2025 @ 7.18% p.a.

US$1.25

Fair Value '25